The UAE has approved Lipfendra, a new daily pill developed by Merck to treat high cholesterol. This development marks the Emirates as the second country in the world to authorize the medication. Clinical trials indicate that the drug reduces LDL cholesterol by up to 59 percent over a 24-week period. The Emirates Drug Establishment states the medication is for adult patients who require medical intervention in addition to maintaining a healthy lifestyle.
High cholesterol is a significant health concern globally, as it is often called a silent killer due to the lack of symptoms. In 2023 alone, LDL cholesterol levels were associated with 3.6 million deaths, representing a third of heart disease fatalities and a quarter of stroke-related deaths. The drug is intended to be used as part of a treatment plan under the supervision of a healthcare professional.
Health experts emphasize that patients can monitor their cholesterol levels through a standard lipid profile blood test. These tests are widely available at pharmacies and medical clinics. Regular screening is recommended for adults to detect high levels early. The introduction of this pill follows other recent approvals by the Emirates Drug Establishment aimed at improving treatment options for cardiovascular conditions and other health challenges.
The regulator notes that patients should continue to prioritize balanced diets and regular physical activity. While the drug provides a new medical tool, it works best when combined with these lifestyle habits. As the country expands its range of authorized treatments, officials reiterate that consulting a doctor is the first step for anyone concerned about their cholesterol levels.